Validation of a Red Blood Cell Transfusion Prediction Model in a Low Transfusion Rate Population.

NCT ID: NCT05581238

Last Updated: 2024-03-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6428 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-01

Study Completion Date

2024-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The transfusion risk and clinical knowledge (TRACK) allogeneic blood transfusion prediction model was developed more than ten years ago and demonstrated good discriminative ability in patients with increased risk for allogeneic blood transfusion in an all Italian population. At the time of derivation, dual anti-platelet medication was suggested in the treatment of acute coronary syndrome, but not yet fully implemented.

The aim of this study is to externally validate the TRACK blood transfusion prediction model in the cardiac surgery population of Medisch Spectrum Twente Thoraxcentrum Twente. Additionally, the impact of adding the preoperative use of dual anti-platelet medication, as additional predictive factor, to the TRACK blood transfusion prediction model will be investigated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiothoracic surgery is associated with increased perioperative blood loss and the need for allogeneic blood and blood product transfusions. This is due to three distinct factors, the invasive nature of the surgical procedures, the need for high dose anti-coagulation during extracorporeal circulation, and lastly the exposure of blood to the internal surface area of the heart-lung machine. Most cardiac patients use anti-platelet therapy before and after surgery, making hemostasis management in this specific patient population even more complex. European guidelines recommend administering anti-platelet therapy using Aspirin in combination with platelet receptor inhibitors such as Clopidogrel, Prasugrel or Ticagrelor, also known as dual anti-platelet therapy in patients with acute coronary syndrome.

Making distinct decisions regarding individual patient hemostasis management remains challenging. Decision making supported by prediction models, such as, EuroSCORE is well established in the cardiac surgery population. A few models pertaining specifically to allogeneic blood transfusion have been created and externally validated. Most of these prediction models perform reasonably well, predicting red blood cell transfusions with seventy-eighty percent accuracy, depending on the model and number of prediction factors used. Some are even excellent for predicting the chance of severe post-operative bleeding. As the transfusion of even one unit of allogeneic blood transfusion impacts mortality, the choice for the best feasible prediction model for routine clinical practice that reflects daily practice, uses a limited number of predictive factors, has a predictive capacity of more than seventy percent, and discriminates between risk groups for allogeneic blood transfusion is desirable.

Transfusion Risk and Clinical Knowledge (TRACK) model validation and optimization The TRACK model was developed more than ten years ago in an Italian adult cardiac surgery population. The decision to validate the TRACK model was based on its simplicity and relatively high predictive capacity, in comparison to other models with higher numbers of complex factors. This model has an allogeneic blood transfusion predictive capacity of seventy-two percent and uses a point system to divide patients into different risk groups, according to the total number of points allocated. During the derivation of this model, dual anti-platelet medication was included, but no significant association was found. In the twelve years since development, the popularity of dual anti-platelet medication used in acute coronary syndrome patients has significantly increased and its association with post-operative bleeding and allogeneic blood transfusion has been suggested.

Recent studies suggest that platelet activity may play a significant role in the prediction of post-operative bleeding, and one research group found that adding platelet activity to the CRUSADE score showed a significant increase in predicting risk of major bleeding in acute coronary syndrome patients. A re-evaluation of the association between dual anti-platelet (DAPT) and allogeneic blood transfusion is necessary. This will be done by the addition of DAPT as an extra predictive factor to the TRACK model, during external validation.

The negative association between mortality and transfusion products is well known. In addition, the related significant increase in hospital costs makes better perioperative hemostasis management crucial. Identifying cardiac surgery patients at risk for blood transfusion pre-operatively would aid clinicians in modifying the perioperative approach with goal the prevention of unnecessary allogeneic blood transfusion and the associated complications thereof.

Validating this model might aid clinicians in reducing allogeneic blood transfusions, transfusion complications and associated costs. Ultimately this might aid for development of patient specific transfusion strategies and new blood management protocols.

The aim of this study is to externally validate the TRACK blood transfusion prediction model in the cardiac surgery population of Medisch Spectrum Twente Thoraxcentrum Twente. Additionally, the impact of adding the preoperative use of dual anti-platelet medication will be studied, as additional predictive factor, to the TRACK blood transfusion prediction model.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Aggregation Blood Transfusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TRACK

External validation of TRACK prediction model with 5 variables: age, weight, sex, pre-op HCT, Type of surgery.

No interventions assigned to this group

TRACK-TCT

New model development with 6 variables. 5 From the TRACK model: age, weight, sex, pre-op HCT, Type of surgery. A sixth variable will be added i.e.: pre-operative P2Y12 drug use

TRACK-TCT

Intervention Type OTHER

An extra variable will be added to an existing prediction model. It is hypothesized that the predictive ability will improve and that better distinction could be made between patients with an increased risk for receiving blood transfusions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TRACK-TCT

An extra variable will be added to an existing prediction model. It is hypothesized that the predictive ability will improve and that better distinction could be made between patients with an increased risk for receiving blood transfusions.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients receiving on-pump cardiac surgery

Exclusion Criteria

* Patients who opted out for reuse of their data for scientific purposes
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medisch Spectrum Twente

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Renard Haumann

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Frank R Halfwerk, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Medisch Spectrum Twente

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Thoraxcentrum Twente

Enschede, Overijssel, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Gorlinger K, Shore-Lesserson L, Dirkmann D, Hanke AA, Rahe-Meyer N, Tanaka KA. Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth. 2013 Aug;27(4 Suppl):S20-34. doi: 10.1053/j.jvca.2013.05.014.

Reference Type BACKGROUND
PMID: 23910533 (View on PubMed)

Raphael J, Mazer CD, Subramani S, Schroeder A, Abdalla M, Ferreira R, Roman PE, Patel N, Welsby I, Greilich PE, Harvey R, Ranucci M, Heller LB, Boer C, Wilkey A, Hill SE, Nuttall GA, Palvadi RR, Patel PA, Wilkey B, Gaitan B, Hill SS, Kwak J, Klick J, Bollen BA, Shore-Lesserson L, Abernathy J, Schwann N, Lau WT. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg. 2019 Nov;129(5):1209-1221. doi: 10.1213/ANE.0000000000004355.

Reference Type BACKGROUND
PMID: 31613811 (View on PubMed)

Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA); Boer C, Meesters MI, Milojevic M, Benedetto U, Bolliger D, von Heymann C, Jeppsson A, Koster A, Osnabrugge RL, Ranucci M, Ravn HB, Vonk ABA, Wahba A, Pagano D. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth. 2018 Feb;32(1):88-120. doi: 10.1053/j.jvca.2017.06.026. Epub 2017 Sep 30. No abstract available.

Reference Type BACKGROUND
PMID: 29029990 (View on PubMed)

Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, Ghannam M, Yeo E, Djaiani G, Karski J. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion. 2004 Oct;44(10):1453-62. doi: 10.1111/j.1537-2995.2004.04144.x.

Reference Type BACKGROUND
PMID: 15383018 (View on PubMed)

Ranucci M, Bozzetti G, Ditta A, Cotza M, Carboni G, Ballotta A. Surgical reexploration after cardiac operations: why a worse outcome? Ann Thorac Surg. 2008 Nov;86(5):1557-62. doi: 10.1016/j.athoracsur.2008.07.114.

Reference Type BACKGROUND
PMID: 19049749 (View on PubMed)

Khan B, Islam MU, Ahmad I, Rehman MU. Modifiable Risk Factors associated with Post-Operative Bleeding and transfusion requirements in Cardiac Surgery. Pak J Med Sci. 2022 Mar-Apr;38(4Part-II):855-861. doi: 10.12669/pjms.38.4.5685.

Reference Type BACKGROUND
PMID: 35634631 (View on PubMed)

Haumann R, Plonek T, Niesten E, Maaskant J, Arens J, van der Palen J, Halfwerk F. Validation and optimization of a blood transfusion prediction model for low transfusion rate adult cardiac surgery. Perfusion. 2025 Apr 19:2676591251334903. doi: 10.1177/02676591251334903. Online ahead of print.

Reference Type DERIVED
PMID: 40252042 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Protocol_TRACK-TCT_v 2.0

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Liberal Transfusion Strategy in Elderly Patients
NCT03369210 ACTIVE_NOT_RECRUITING PHASE3
Fibrinogen Early In Severe Trauma StudY II
NCT05449834 RECRUITING PHASE3
Tranexamic Acid in Major Vascular Surgery
NCT02335359 COMPLETED PHASE4